{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:49:20Z","timestamp":1788274160773,"version":"build-2803163510"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,12]]},"DOI":"10.7759\/cureus.13302","type":"journal-article","created":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T11:33:57Z","timestamp":1613129637000},"source":"Crossref","is-referenced-by-count":4,"title":["Diabetic Ketoacidosis Secondary to New Onset Type 1 Diabetes Mellitus Related to Pembrolizumab Therapy"],"prefix":"10.7759","author":[{"given":"Andrea","family":"Hernandez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassem","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parth","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnathan","family":"Frunzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-18-0153","article-title":"A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma","volume":"18","author":"Hakami OA","year":"2019","unstructured":"Hakami OA, Ioana J, Ahmad S, Tun TK, Sreenan S, McDermott JH. A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma. Endocrinol Diabet Metabol Case Rep. 2019, 18:0153. 10.1530\/EDM-18-0153","journal-title":"Endocrinol Diabet Metabol Case Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-015-0078-9","article-title":"Pembrolizumab","volume":"3","author":"Khoja L","year":"2015","unstructured":"Khoja L, Butler MO, Kang SP, Ebbinghaus S, Joshua AM. Pembrolizumab. J ImmunoTher Cancer. 2015, 3:36. 10.1186\/s40425-015-0078-9","journal-title":"J ImmunoTher Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-018-9463-2","article-title":"Thyroid disorders induced by checkpoint inhibitors","volume":"19","author":"Ferrari SM","year":"2018","unstructured":"Ferrari SM, Fallahi P, Galetta F, Citi E, Benvenga S, Antonelli A. Thyroid disorders induced by checkpoint inhibitors. World J Oncol. 2018, 19:325-333. 10.1007\/s11154-018-9463-2","journal-title":"World J Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1085w","article-title":"Autoimmune diabetes associated with pembrolizumab: a review of published case reports","volume":"9","author":"Cheema A","year":"2018","unstructured":"Cheema A, Makadia B, Karwadia T, Bajwa R, Hossain M. Autoimmune diabetes associated with pembrolizumab: a review of published case reports. World J Oncol. 2018, 9:1-4. 10.14740\/wjon1085w","journal-title":"World J Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00728","article-title":"Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus","volume":"103","author":"Clotman K","year":"2018","unstructured":"Clotman K, Janssens K, Specenier P, Weets I, De Block CEM. Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus. J Clin Endocrinol Metab. 2018, 103:3144-3154. 10.1210\/jc.2018-00728","journal-title":"J Clin Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000012907","article-title":"Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient: a case report","volume":"97","author":"Li S","year":"2018","unstructured":"Li S, Zhang Y, Sun Z, Hu J, Fang C. Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient: a case report. Medicine. 2018, 97:e12907. 10.1097\/md.0000000000012907","journal-title":"Medicine"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/45182-diabetic-ketoacidosis-secondary-to-new-onset-type-1-diabetes-mellitus-related-to-pembrolizumab-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:24:03Z","timestamp":1707506643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/45182-diabetic-ketoacidosis-secondary-to-new-onset-type-1-diabetes-mellitus-related-to-pembrolizumab-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,12]]},"references-count":6,"URL":"https:\/\/doi.org\/10.7759\/cureus.13302","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,12]]}}}